Fulcrum therapeutics® appoints sonja l. banks to its board of directors

Cambridge, mass., nov. 17, 2021 (globe newswire) -- fulcrum therapeutics, inc.  (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of sonja l. banks to the company's board of directors, effective december 8. ms. banks is currently the chief executive officer of the international dyslexia association and was formerly president of the sickle cell disease association of america (scdaa). she brings nearly 25 years of experience in patient advocacy, community outreach and non-profit leadership, and she is deeply respected for her grassroots work in the rare disease and sickle cell disease communities.
FULC Ratings Summary
FULC Quant Ranking